Chief Legal Officer · Tango Therapeutics, Inc. (TNGX)

Douglas Barry

FY2024 is the first fiscal year CompBrief holds for Douglas Barry as a named executive officer of Tango Therapeutics; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2024

$2,094,450

Salary $451,200Stock awards $280,709

4th of 4 named executive officers at Tango Therapeutics by FY2024 total.

4 named officers on file for Tango Therapeutics, FY2024

Douglas Barry’s pay file — $29

  • 1 fiscal year of pay, line by line
  • 2 equity grants, each cited to its filing
  • TNGX’s disclosed peer group of 18 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Tango Therapeutics’s whole pay program stands against its peers

  • Tango Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on TNGX→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 21, 2025 (DEF 14A).

Free

Get Douglas Barry’s full pay file as a PDF — free

More than this page: up to 10 years of Douglas’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Douglas Barry compensation by year

Tango Therapeutics Summary Compensation Table · the one fiscal year held
In US dollars, as Tango Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2024
Salary$451,200
Bonus$0
Stock awards$280,709
Option awards$1,139,519
Non-equity incentive$204,845
Pension and deferred compensation$0
All other$18,177
Total$2,094,450

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Tango Therapeutics, Inc. DEF 14A filed April 21, 2025, accession 0000950170-25-056230, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Tango Therapeutics, Inc. filed document, accession 0000950170-25-056230. Every figure is read from that document and cited to the page and table it appears in. Filed April 21, 2025.

Equity holdings

unvested awards at FY2024 year-end
TypeUnvested unitsValue at year-endExercise price
RSU22,859$70,634—
RSU15,932$49,230—
Option74,684—$5.20
Option137,156—$12.28
Option41,050—$9.56
Option18,823—$9.22

Per the Outstanding Equity Awards at Fiscal Year-End table in Tango Therapeutics, Inc.'s FY2024 proxy; value at the fiscal year-end close, as the company printed it.

Tango Therapeutics’s named executive officers, FY2024

as the company reported each
Named executive officerRoleFY2024 total
Barbara WeberPresident, Chief Executive Officer and Director$6,541,200
Adam CrystalPresident of Research and Development$3,777,318
Daniella BeckmanChief Financial Officer$3,166,290
Douglas Barry · this pageChief Legal Officer$2,094,450

The full Tango Therapeutics compensation record

free company brief

This page is one person within Tango Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the Tango Therapeutics proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Tango Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Douglas Barry's compensation dossier · One-time report. No refunds.